Glenmark Pharmaceuticals and Canadian biotech firm SaNOtize Research & Development Corp. today announced an exclusive long term strategic partnership to manufacture, market and distribute its breakthrough Nitric Oxide Nasal Spray (NONS) for COVID]19 treatment in India and other Asian markets including Singapore, Malaysia, Hong Kong, Taiwan, Nepal, Brunei, Cambodia, Laos, Myanmar, Sri Lanka, Timor]Leste and Vietnam.
Available in the form of a simple nasal spray, it is designed to kill the virus in the upper airways, preventing it from incubating and spreading to the lungs. It is based on nitric oxide (NO), a natural nano]molecule with proven anti]microbial properties, and which has a direct effect on SARS]CoV]2, the virus causing COVID]19.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
